Trial 0C-22-7


A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes.

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Immunomodulator
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Negeen Izadian, Coordinator, Clara Karam, D.M., Nazeli Livaskani, Coordinator, Stephanie Kim, Coordinator, Maura Fernandez, D.M., Christina Nakhoul, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.